Species: Poultry, pigs and an increasing presence in cattle.
Key therapeutic sectors: Water soluble antibiotics, poultry vaccines, locomotion (lameness) and pain management.
Products: Our products are predominately POMs that are prescribed by veterinarians who work in either specialist veterinary practices or professional farming units.
As over 60% of all global animal health sales are FAP, Dechra is underweight relative to the market and our competitors and it is an increasing area of focus.
The key driver for growth in this sector is a huge increase in the global demand for high quality animal protein and dairy products. Vaccines are the biggest growth sector of the veterinary market and are anticipated to continue to outgrow therapeutic treatments.
There is also a growing awareness to the need for better animal welfare standards, including pain control during procedures such as pig castration and tail docking.
Dechra entered the FAP sector through the acquisition of Eurovet in 2012; it currently represents 11.9% of revenue. The majority of our sales are currently antibiotics which are sold mainly into Western Europe. This market has been extremely proactive over the last five years in reducing antibiotic use due to concerns over antimicrobial resistance and ‘super bugs’.
Dechra’s portfolio is positioned to match current best practice prescribing habits; additionally, our recent move into poultry vaccines should provide growth opportunities in future years as we seek global registrations.